Tofacitinib for slate grey colouration of skin

Efficacy of tofacitinib in acquired dermal macular hyperpigmentation: An open label pilot study - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/03/064633

Enrollment

Registered

2024-03-21

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L818- Other specified disorders of pigmentation

Interventions

Intervention1: Tofacitinib: Tofacitinib shall be started at a dose of 5 mg twice a day. This dose would be continued for 24 weeks or until complete disease resolution, whichever is earlier. Control In

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with a clinicopathological diagnosis of ADMH 2. Consenting for participation in the study

Exclusion criteria

Exclusion criteria: 1. Pregnancy/Lactation 2. Patients with severe hepatic, renal disease or dyslipidemia 3. Pre-existing malignancy 4. Any other contraindication to use of tofacitinib

Design outcomes

Primary

Measure	Time frame
Percentage and absolute reduction in DPASI plusTimepoint: At week 24	—

Secondary

Measure	Time frame
Percentage and absolute reduction in D-PASI, at week 24.Timepoint: At week 24;Percentage improvement in PA scoresTimepoint: At week 24	—

Countries

India

Contacts

Public ContactDavinder Parsad

Post Graduate Institute of Medical Education and Research

parsad@me.com01722756564

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026